^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Cilcane (cilengitide) (Integrin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
Excerpt:
MGMT status... The overall survival stratified by MGMT status at the baseline alone for all 112 patients...The estimated median OS of patients who were methylated, unmethylated and unknown 30 months (95% CI: 16.6-35.4 months), 19.1 months (95% CI: 14.6-21.9 months), and 17.4 months (95% CI: 13.7-24.2 months), respectively. MGMT status... The overall survival stratified by MGMT status at the baseline alone for all 112 patients...The estimated median OS of patients who were methylated, unmethylated and unknown 30 months (95% CI: 16.6-35.4 months), 19.1 months (95% CI: 14.6-21.9 months), and 17.4 months (95% CI: 13.7-24.2 months), respectively.
Secondary therapy:
temozolomide
DOI:
10.1002/cncr.27585
